AstraZeneca and Daiichi Sankyo withdraw EU application for datopotamab deruxtecan in NSCLC after Phase III trial shows no ...

Viatris faces US FDA regulatory action on its Indore, India facility, with a warning letter and import alert restricting 11 ...

US pharma major Bristol Myers Squibb has announced positive results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055 ...

The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza ...

The US subsidiary of Japan’s Sumitomo Pharma announced that the US Food and Drug Administration (FDA) has approved Gemtesa ...

USA-based immunology company RAPT Therapeutics has entered into an exclusive license agreement with Shanghai Jemincare ...

USA-based clinical-stage biopharma Traws Pharma saw its shares leap more than 150% to $12.57 as it announced progress in the ...

Shionogi to acquire full ownership of its joint ventures with Ping An subsidiaries, dissolving partnerships to refocus on ...

XBiotech halts rheumatology program after Phase II trial failure for rheumatoid arthritis, citing data irregularities and ...

US pharma major Eli Lilly today announced the US Food and Drug Administration (FDA) approved Zepbound its (tirzepatide) as ...

AstraZeneca gains EU approval for Tagrisso to treat unresectable locally advanced NSCLC based on Phase III LAURA data showing ...

New York-based Nuvation Bio today announced that the FDA has accepted the company’s new drug application (NDA) for ...